Latigo Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027 Company plans to add oxycodone/acetaminophen (commonly known as Percocet) as opioid comparator arm to the Phase 3 bunionectomy trial Phase 2 trial of LTG-321 for the treatment of chronic pain is currently ongoing; Expect to report topline results in the second half of 2027 Cash and cash equivalents of $401 million expected to fund operations into 2029 THOUSAND OAKS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (NASDAQ:LTGO), a clinical-stage biopharmaceutical company committed to developing innovativ